EU ‘Vaccine Hesitancy’ And Why It’s A Problem For Manufacturers And Public Health
Executive Summary
“Vaccine hesitancy” – the gradual decline in rates of vaccination against preventable diseases – has led to outbreaks of illnesses such as measles in several European countries, fueled by factors such as complacency and lack of trust or access to vaccines. Ian Schofield spoke to Patricia Massetti, associate vice-president and European vaccines lead at MSD, and Andrea Ammon, the new director of the ECDC, about the implications of vaccine hesitancy, including what can be done to counter it, and the difficulty of planning vaccine manufacture for predicted future outbreaks.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.